This is the honest version of a fight that is still live. Several meta-analyses do find reduced cardiovascular mortality with marine omega-3, and REDUCE-IT showed a large benefit — but REDUCE-IT tested a prescription drug, icosapent ethyl, against mineral oil, and STRENGTH tested 4 g/day of EPA+DHA against corn oil and found nothing at all. Meanwhile VITAL, the largest primary-prevention trial, was negative, and pooled randomized evidence links marine omega-3 supplementation to an increased risk of atrial fibrillation, greatest above 1 g/day. We publish both halves.
Omega-3 fatty acids are long-chain polyunsaturated fats, principally eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), found mainly in oily fish and fish oil; a plant-derived form, alpha-linolenic acid (ALA), occurs in walnuts and flaxseed. Because the body cannot synthesize them, they must be obtained from diet or supplements. EPA and DHA are incorporated into cell membranes and act as substrates for specialized pro-resolving lipid mediators (resolvins, protectins and maresins) that help resolve inflammation. Their most consistent metabolic effect is a dose-dependent lowering of blood triglycerides.
Claims below are supported by the primary sources linked under each line — the same sources we cite on the product page.
Each line pairs a claim that circulates in marketing and forums with the trial result that contradicts or narrows it.
Quotations are verbatim from the cited paper. Negative and inconclusive trials are listed alongside the positive ones because that is the whole point of this page.
“Supplementation with n-3 fatty acids did not result in a lower incidence of major cardiovascular events or cancer than placebo.”
“In 13,078 high-risk patients (STRENGTH), 4 g/day EPA+DHA carboxylic acids showed no cardiovascular benefit over corn oil (HR 0.99), with more atrial fibrillation in the omega-3 group.”
“In RCTs examining cardiovascular outcomes, marine ɷ-3 supplementation was associated with an increased risk of AF. The risk appeared to be greater in trials testing >1 g/d.”
“A primary end-point event occurred in 17.2% of the patients in the icosapent ethyl group, as compared with 22.0% of the patients in the placebo group (hazard ratio, 0.75; 95% confidence interval [CI], 0.68 to 0.83; P<0.001)”
“In 415,737 UK Biobank participants, regular fish-oil use was associated with higher incident atrial fibrillation (HR 1.13) in people without cardiovascular disease, yet with slower progression to adverse events in those with existing disease.”
Across large randomized trials and meta-analyses, marine omega-3s reliably reduce serum triglycerides (roughly 15% at higher doses) and modestly lower blood pressure and resting heart rate, but their effect on cardiovascular events is mixed and depends on dose, formulation and population. High-dose purified EPA (icosapent ethyl) reduced ischemic events by 25% in the REDUCE-IT trial in statin-treated patients with elevated triglycerides, whereas 1 g/day of EPA+DHA showed little overall benefit in the VITAL primary-prevention trial, high-dose EPA+DHA carboxylic acids were no better than corn oil in the STRENGTH trial, and Cochrane concluded supplements have little or no effect on all-cause or cardiovascular mortality. High doses (above 1 g/day) also raise the risk of atrial fibrillation - in a large UK Biobank cohort, regular fish-oil use was associated with a 13% higher risk of incident atrial fibrillation in people without cardiovascular disease, though possibly with benefit once disease is established - so benefits and harms must be weighed. This evidence describes the EPA/DHA compounds and their mechanisms in human health, not this specific commercial product.
A grade that cannot be falsified is a marketing claim. These are the specific results that would move this one up.
If your triglycerides are high, this is the effect omega-3 reliably produces, and it is dose-dependent. If you are taking more than 1 gram a day of EPA+DHA, the atrial fibrillation signal is worth a conversation with your physician, particularly if you have any arrhythmia history. And if you want to know whether you need it at all, the omega-3 index is one of the few supplement questions that can simply be measured rather than assumed.
Graded as a measurement tool with an actual target range — the rare case where you can test instead of guess.
Graded Strong. Blood pressure is a cardiovascular lever with unambiguous outcome evidence behind treating it.
The lipid particle number that tracks cardiovascular risk more cleanly than the panel most labs print by default.
EPA versus DHA, dose, oxidation, third-party testing — if you are buying anyway.
Omega-3 molecule page · Omega-3 and aging: what the best trials show · The omega-3 index: a supplement test with a target range · Your watch thinks you have AFib. Read the fine print. · Sardine toast — omega-3 from food · The graded supplement guide
Sibling pages in this record: NMN (nicotinamide mononucleotide) · Resveratrol · Vitamin D · Blue-light filtering glasses
It depends on which question you are asking. For lowering triglycerides, yes, reliably and dose-dependently. For preventing cardiovascular events in the general population, the largest trial — VITAL — was negative, and the closest high-dose comparison trial to REDUCE-IT, which was STRENGTH, was also negative. Several meta-analyses do find benefit. We grade it Moderate because that is what genuinely mixed randomized evidence looks like.
A meta-analysis of cardiovascular outcome trials found marine omega-3 supplementation associated with increased atrial fibrillation risk, appearing greater above 1 g/day, and a large UK Biobank cohort found higher incident AF among regular fish-oil users without pre-existing cardiovascular disease. It is not a reason for panic at food-level intakes, and it is a reason to discuss high-dose supplementation with your physician.
Because it is the one large trial with a dramatic positive result. It also tested a prescription drug rather than a supplement, used a mineral-oil comparator that has been questioned, and was not replicated when a similar dose of EPA+DHA was tested against corn oil in STRENGTH. Quoting REDUCE-IT without STRENGTH is the specific move this page exists to flag.
Dietary intake is where the observational signal is strongest and where the AF question does not arise in the same form. We are not a diet programme, but the food route is genuinely the lower-risk version of this, and we publish recipes built around it.